A comparison of genotyping platforms for pharmacogenetic testing

As the scientific evidence base for pharmacogenetics continues to expand, the use of such information in clinical management and drug development will be in demand.
The FDA advises that the incorporation of genetic testing into clinical trials should be a routine consideration at the outset of a drug development program and promotes the advantages of companion diagnostic endeavors. Laboratories that conduct this testing require the most robust and flexible technologies in order to succeed. PGXL Laboratories is an industry leader in the development and evaluation of pharmacogenetic tests. In particular, research efforts have focused on a rigorous approach to the assessment and validation of alternative technology options and implementation strategies. This includes molecular methodology, instrument capacity, cost, customization options, and workflow. Data comparing two leading technology platforms and the advantages and disadvantages therein will be discussed. Participants will be able to critically evaluate varying technologies and understand appropriate implementation scenarios for pharmacogenetic testing.